Stockscreener 앱 받기
9.38
1.47%
-0.14
시간 외 거래:
9.44
0.06
+0.64%
전일 마감가:
$9.52
열려 있는:
$9.55
하루 거래량:
3.57M
Relative Volume:
1.33
시가총액:
$2.10B
수익:
$509.86M
순이익/손실:
$165.35M
주가수익비율:
13.84
EPS:
0.6779
순현금흐름:
$107.55M
1주 성능:
+2.96%
1개월 성능:
-3.50%
6개월 성능:
-2.60%
1년 성능:
-38.77%
1일 변동 폭
$9.23
$9.625
1주일 범위
$9.10
$9.84
52주 변동 폭
$7.2101
$20.46
Adma Biologics Inc Stock (ADMA) Company Profile
명칭
Adma Biologics Inc
전화
(201) 478-5552
주소
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
9.38 | 2.10B | 509.86M | 165.35M | 107.55M | 0.6779 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-21 | 개시 | Canaccord Genuity | Buy |
| 2026-03-26 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-07-19 | 재개 | Raymond James | Strong Buy |
| 2022-10-13 | 개시 | Mizuho | Buy |
| 2021-11-11 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2021-11-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-04 | 개시 | Jefferies | Buy |
| 2019-04-15 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-07 | 재개 | H.C. Wainwright | Buy |
| 2017-12-11 | 재확인 | Maxim Group | Buy |
| 2017-11-14 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2017-01-23 | 업그레이드 | Maxim Group | Hold → Buy |
| 2016-08-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2016-07-25 | 재확인 | Maxim Group | Buy |
| 2015-05-13 | 재확인 | Maxim Group | Buy |
| 2014-12-08 | 개시 | Oppenheimer | Outperform |
| 2014-12-01 | 재확인 | Maxim Group | Buy |
모두보기
Adma Biologics Inc 주식(ADMA)의 최신 뉴스
ADMA Biologics Inc (ADMA) Stock Forecasts - Yahoo! Finance Canada
(ADMA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Why Adma Biologics (ADMA) Dipped More Than Broader Market Today - Yahoo Finance
Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It? - Yahoo Finance
ADMA Biologics Inc (ADMA) Stock Analysis: Potential Upside of 86.61% Sparks Investor Interest - DirectorsTalk Interviews
Adma Biologics Stock Price Forecast. Should You Buy ADMA? - StockInvest.us
Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know - finance.yahoo.com
ADMA Biologics IncCommon Stock (Nasdaq:ADMA) Price Chart - The Chronicle-Journal
ADMA Biologics Inc (ADMA) Stock Analysis: A Biotech Gem With 84% Upside Potential - DirectorsTalk Interviews
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Adma Biologics (ADMA) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
ADMA Stock Downgraded By Cantor As ‘Channel Stuffing’ Claims Shake Investor Confidence - Stocktwits
ADMA: Adma Biologics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True? - Yahoo Finance
ADMAAdma Biologics Inc Volatility & Greeks - Finviz
ADMA Biologics Inc (ADMA) Stock Analysis: A Biotech With 76% Potential Upside - DirectorsTalk Interviews
Adma Biologics (ADMA) Down 4.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Trading Systems Reacting to (ADMA) Volatility - Stock Traders Daily
ADMA Tumbles On Slashed Outlook As Short-Seller Aftermath Meets Competitive Headwinds - stocktwits.com
ADMA Biologics: Maybe The Bears Are Right (Rating Downgrade) (NASDAQ:ADMA) - Seeking Alpha
ADMA Biologics Inc (ADMA) Stock Analysis: Exploring A Promising 82% Potential Upside - DirectorsTalk Interviews
ADMA BIOLOGICS, INC. (ADMA) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty - TMX Newsfile
Class action lawsuit filed against ADMA Biologics for misleading investors and undisclosed transactions - Pluang
Law firm probes ADMA Biologics' leadership for possible breaches of fiduciary duty - Pluang
Nomura Small Cap Growth Fund's ADMA Biologics Inc(ADMA) Holding History - GuruFocus
Investigation launched into ADMA Biologics for alleged revenue inflation via channel-stuffing. - Pluang
ADMA Biologics Inc (ADMA) Stock Analysis: Unpacking the 79% Potential Upside for Investors - DirectorsTalk Interviews
ADMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ADMA Biologics Inc (NASDAQ:ADMA) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Bank of America Corp DE Raises Holdings in ADMA Biologics Inc $ADMA - MarketBeat
Why ADMA Biologics (ADMA) Is Up 5.6% After Reaffirming 2026 Revenue Guidance And EPS Momentum - Sahm
Behavioral Patterns of ADMA and Institutional Flows - Stock Traders Daily
ADMA|ADMA Biologics Inc|Price:9.540|Chg%:+0.200 - TradingKey
STATE STREET CORP Buys ADMA Biologics Inc (ADMA) -- Shares Look 49% Undervalued on GF Value - GuruFocus
ADMA Biologics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Can Asceniv Help ADMA Stock Combat IG Market Challenges? - Yahoo Finance
ADMA Biologics: The Earnings Reset Still Leaves More Upside (NASDAQ:ADMA) - Seeking Alpha
Royal Bank of Canada Buys 759,984 Shares of ADMA Biologics Inc $ADMA - MarketBeat
Janus Henderson Group PLC Trims Stock Holdings in ADMA Biologics Inc $ADMA - MarketBeat
ADMA DEADLINEFINAL REMINDER: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of ADMA Biologics, Inc. to Contact the Firm Today! - ACCESS Newswire
ADMA Biologics, Inc. Deadline: ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, - GlobeNewswire
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law - Business Wire
Adma Biologics Inc (ADMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):